Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Autologous bone marrow transplant
What an autologous bone marrow transplant involves, how stem cells are harvested and returned, what clinical evidence indicates for lymphoma and myeloma, who qualifies, how approximate costs in Turkey compare with the UK, US and Germany, what hospitalisation and engraftment entail, potential complications and how to choose an accredited bone marrow transplant centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Autologous Bone Marrow Transplant
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is an autologous bone marrow transplant and how does it work?
An autologous bone marrow transplant (also called an autologous haematopoietic stem cell transplant) uses a patient's own healthy blood-forming stem cells to restore bone marrow function after high-dose chemotherapy. In conditions such as multiple myeloma and relapsed lymphoma, intensive doses of cytotoxic medicine are necessary to destroy resilient malignant cells. However, these regimens also wipe out healthy blood-producing cells in the marrow. By harvesting and cryopreserving healthy stem cells beforehand, haematologists can safely deliver intensive conditioning therapy and subsequently reinfuse the stored cells to rebuild the blood and immune system.
Because the cells come from your own body, there is no risk of graft-versus-host disease (GvHD). The primary aim is haematological rescue: restoring red blood cells, infection-fighting white blood cells, and platelets. Specialised centres providing an autologous bone marrow transplant Turkey pathway operate dedicated units adhering to strict infection-control standards. For broader oncology information, see our guide to oncology treatments in Turkey (hub).
Does an autologous bone marrow transplant actually work?
Clinical data confirms that an autologous bone marrow transplant is an effective treatment for specific haematological malignancies. International registries, including the European Society for Blood and Marrow Transplantation (EBMT) and CIBMTR, recognise autologous transplantation as the standard of care for consolidating first remissions in multiple myeloma and treating chemosensitive relapses in Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL).
Trials demonstrate that high-dose therapy followed by autologous rescue substantially prolongs progression-free survival compared with standard chemotherapy alone. However, it is not an absolute cure for every patient. Because the reinfused cells are the patient's own, they do not produce an immune graft-versus-tumour attack. Relapse remains possible, particularly if the disease did not respond well to pre-transplant induction therapy. For acute leukaemias, allogeneic transplants from a donor are usually required instead.
Autologous bone marrow transplant cost in Turkey compared with the UK, US and Germany
The figures below outline approximate international cost ranges for an autologous haematopoietic stem cell transplantation programme. They represent broad estimates rather than specific hospital quotes. Final prices depend on the required conditioning regimen, inpatient isolation duration, and supportive transfusion needs.
| Country | Approximate cost range |
|---|---|
| Turkey | €30,000 – €55,000 |
| United Kingdom | €70,000 – €130,000 |
| United States | €150,000 – €350,000 |
| Germany | €65,000 – €120,000 |
What influences the autologous bone marrow transplant price: pre-transplant restaging scans, the number of apheresis sessions needed to collect adequate CD34-positive cells, cryopreservation duration, and medications. Understanding the overall autologous bone marrow transplant cost helps patients plan. Packages in Turkey typically include pre-transplant workups, stem cell harvesting, conditioning drugs, three to four weeks in a HEPA-filtered private room, laboratory monitoring, and initial outpatient follow-ups. You can request a personalised estimate through our free quote service.
Autologous transplant, allogeneic transplant or CAR-T cell therapy?
Advanced haematological treatments differ in cell source, biological mechanism, and risk profiles. An autologous transplant uses your own harvested cells, an allogeneic transplant uses stem cells from a matched donor, and CAR-T cell therapy genetically re-engineers your T-cells to attack cancer targets.
| Method | Best suited to | Typical limits |
|---|---|---|
| Autologous stem cell transplant | Multiple myeloma consolidation; relapsed chemosensitive Hodgkin and non-Hodgkin lymphomas | No graft-versus-tumour effect; requires healthy marrow reserves; disease can relapse |
| Allogeneic bone marrow transplant | Acute myeloid leukaemia (AML); acute lymphoblastic leukaemia (ALL); severe aplastic anaemia | Requires compatible donor; significant risk of graft-versus-host disease; higher treatment risks |
| CAR-T cell therapy | Relapsed or refractory large B-cell lymphomas; refractory multiple myeloma after multiple lines | Complex laboratory manufacturing; risk of cytokine release syndrome; high acquisition cost |
The choice depends on tumour genetics, remission status, and organ fitness. For wider context on systemic therapies, see our guide to oncology treatments in Turkey.
Who is an eligible candidate for an autologous stem cell transplant?
Eligibility requires detailed physiological and oncological assessments. Haematologists evaluate medical fitness using scoring systems such as the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) and ECOG performance status.
Suitable candidates generally meet the following criteria:
- Chemosensitive disease showing at least a partial response to induction chemotherapy;
- Adequate cardiac function, documented by an echocardiogram (LVEF above 45–50%);
- Sufficient pulmonary function, confirmed by spirometry and diffusion capacity (DLCO);
- Preserved kidney and liver function capable of processing high-dose drugs;
- Absence of active, uncontrolled bacterial, fungal, or viral infections.
Patients with chemoresistant disease, severe cardiac failure, advanced pulmonary disease, or irreversible liver dysfunction are generally not suitable. Chronological age is less critical than overall biological fitness and organ reserve.
The transplantation process: from stem cell collection to engraftment
The autologous bone marrow transplant procedure follows four consecutive steps:
1. Mobilisation and harvesting
Stem cells normally live inside bone marrow. To bring them into the bloodstream, patients receive daily injections of growth factors (G-CSF), sometimes with plerixafor. Once blood counts confirm enough circulating CD34-positive cells, apheresis begins. Blood passes through a specialised machine that separates stem cells and returns the remaining blood to the patient. Harvested cells are frozen in liquid nitrogen.
2. Conditioning chemotherapy
The patient enters a protective hospital room. Over several days, high-dose chemotherapy (such as melphalan or BEAM) is administered to eradicate remaining cancer cells and clear space in the marrow.
3. Stem cell infusion (Day 0)
After chemotherapy clears from the body, the frozen stem cells are thawed at the bedside and infused through a central venous catheter. The cells travel through the bloodstream and settle into the bone marrow.
4. Aplastic phase and engraftment
For 10 to 14 days, blood counts remain extremely low. Patients receive protective isolation, prophylactic antibiotics, and blood transfusions. Engraftment occurs when the new cells begin producing blood, defined as an absolute neutrophil count above 500 for three consecutive days.
What results and remission outcomes can patients realistically expect?
In haematology, results are assessed through laboratory markers and imaging rather than cosmetic before-and-after photographs. Baseline PET-CT scans and bone marrow biopsies document active disease before treatment, while post-transplant restaging scans evaluate remission depth.
For multiple myeloma, transplantation frequently turns a partial response into complete remission or minimal residual disease (MRD) negativity, supporting years of disease control when combined with maintenance therapy. For relapsed Hodgkin and non-Hodgkin lymphomas, it provides a proven opportunity for long-term remission. However, scans cannot detect individual microscopic cells, making ongoing monitoring and maintenance therapy critical components of care.
Hospital stay in Turkey and the long-term recovery timeline
An autologous bone marrow transplant in Turkey generally requires a stay of six to ten weeks for international patients.
The first week involves pre-transplant tests and stem cell harvesting. Inpatient hospitalisation lasts about three to four weeks, covering conditioning chemotherapy, infusion, and the neutropenic period. Patients stay in private rooms with positive-pressure HEPA filtration to prevent infections. Once engraftment is confirmed and oral intake is normal, patients move to nearby outpatient accommodation.
Outpatient monitoring continues for three to four weeks with regular blood checks before clearance to travel home. When managing autologous bone marrow transplant recovery, remember that full immune recovery takes 6 to 12 months. Patients must practice strict food safety, avoid crowded environments, and undergo revaccination after their immune system matures.
Risks and potential complications of high-dose conditioning
Intensive conditioning and marrow suppression carry clear risks that require specialised hospital care. Guidance from the NHS, EBMT, and ASTCT outlines several well-documented complications:
- Infection and neutropenic fever: Depleted white blood cells leave patients vulnerable to bacterial, fungal, and viral infections, requiring prompt intravenous antibiotics;
- Mucositis: Inflammation of the digestive tract lining causes mouth ulcers, sore throat, and diarrhoea, managed with pain relief and nutritional support;
- Bleeding and anaemia: Low platelets and red blood cells cause fatigue and bruising, requiring irradiated blood transfusions;
- Organ strain: High-dose drugs can temporarily affect kidney, liver, or heart function;
- Secondary malignancies: Intensive chemotherapy carries a small long-term risk of secondary blood disorders.
Because the procedure uses your own cells, graft-versus-host disease and graft rejection do not happen. Treatment-related mortality in established centres is typically low, usually between 1% and 3%.
How to select an accredited transplant centre and red flags to watch for
Selecting a transplant centre requires verifying clinical accreditations and medical infrastructure. Look for hospitals accredited by Joint Commission International (JCI) or those following JACIE quality standards. A suitable facility must have dedicated HEPA-filtered positive-pressure rooms, an on-site apheresis and cryopreservation laboratory, an accredited blood bank, and a fully equipped intensive care unit.
Red flags include clinics offering transplants without dedicated haematology units, quotes that omit isolation or transfusion costs, promises of guaranteed cures, and no post-discharge telemedicine support. Review our guide on how it works for international coordination, and ensure an experienced haematologist evaluates your case before you travel.
Key questions to ask your haematology transplant team
Before proceeding with treatment abroad, ask your clinical team these essential questions:
- Which conditioning chemotherapy regimen do you recommend for my diagnosis, and why?
- What target CD34-positive cell count must be collected before conditioning starts?
- How many autologous transplants does your centre perform each year?
- Does the hospital have positive-pressure HEPA-filtered rooms and JACIE or JCI accreditation?
- What is the standard protocol if engraftment takes longer than expected?
- What are the out-of-pocket costs if additional hospital days or transfusions are required?
- How will your team share medical records and coordinate follow-up with my home haematologist?
You can read more about how it works or request a consultation through our free quote page.
Hospitals with Oncology in Turkey
Frequently asked questions
An autologous bone marrow transplant, or autologous stem cell transplant, collects healthy blood-forming stem cells from your own body, freezes them, and reinfuses them following high-dose chemotherapy. The primary purpose is haematological rescue, allowing oncologists to deliver intensive conditioning treatments that destroy resistant cancer cells while restoring normal marrow function.
Clinical trials and haematology registries demonstrate that autologous transplantation effectively deepens remissions and extends progression-free survival, particularly in multiple myeloma and relapsed lymphomas. It is not an absolute cure for every patient, and success depends on disease staging, genetic risk markers, and response to previous chemotherapy lines.
The procedure generally ranges from approximately €30,000 to €55,000 in Turkey, compared with €70,000 to €130,000 in the UK and higher in the US. The total sum reflects mobilisation medication, apheresis collection, laboratory cryopreservation, high-dose conditioning drugs, positive-pressure HEPA isolation room accommodation, and supportive transfusions.
Unlike surgical procedures, outcomes are measured through metabolic scans and laboratory markers rather than physical images. Before transplantation, scans show active disease volume; afterwards, PET-CT scans and marrow biopsies evaluate whether complete metabolic remission or minimal residual disease negativity has been achieved.
Initial physical recovery and neutrophil engraftment require two to three weeks within an inpatient isolation room. Outpatient monitoring continues for another four to six weeks. Full immune reconstitution takes between six and twelve months, during which patients follow infection precautions and dietary safeguards.
Stem cell collection and reinfusion cause minimal physical sensation, similar to a standard blood transfusion. Discomfort primarily arises from chemotherapy side effects, particularly oral mucositis, fatigue, nausea, and temporary bone aching from mobilisation medications, which the medical team manages with supportive therapies.
Remission duration varies substantially by diagnosis. In multiple myeloma, consolidation transplantation often provides several years of disease control when paired with maintenance medication. In relapsed Hodgkin or aggressive non-Hodgkin lymphomas, patients achieving durable remissions past two to five years may remain disease-free over the long term.
Autologous transplants carry significantly lower mortality rates than allogeneic procedures because there is zero risk of graft-versus-host disease. However, the temporary depletion of white blood cells creates vulnerability to severe infections, requiring strictly monitored HEPA-filtered isolation rooms, prophylactic antimicrobial drugs, and rapid intervention protocols.
An autologous transplant utilises your own harvested stem cells to restore marrow following chemotherapy, eliminating graft rejection risks. An allogeneic transplant uses stem cells from a matched family or unrelated donor, introducing an immune graft-versus-tumour effect against aggressive leukaemias, but carrying high risks of graft-versus-host disease.
Patients typically spend between six and ten weeks in Turkey. This window covers preliminary staging investigations, mobilisation and apheresis, two to three weeks of inpatient isolation following conditioning chemotherapy until blood counts recover, and two to four weeks of outpatient monitoring before clearance to fly home.
Patient stories